American Conference Institute (ACI) will be holding its 16th annual Drug and Medical Device Litigation conference on December 5-7, 2011 in New York, NY. The conference will allow attendees to:
• Strengthen class action strategies by factoring favorable recent judicial decisions into new defense tactics;
• Master the challenges created by the increased focus on the conduct of individual executives and weigh potential "fraud on the FDA";
• Plan an exit strategy and select the most advantageous settlement model;
• Prevent an MDL from becoming a runaway proceeding with front-end logistical strategies;
• Comply with new industry disclosure requirements after Matrixx;
• Develop game-changing defense tactics incorporating evidence from social media; and
• Dissect and explain complex medical and scientific information.
In particular, ACI's faculty will offer presentations on the following topics:
• Applying favorable recent judicial decisions and policy trends to strengthen your class actions defense strategies;
• Spotlight remarks: Case management and settlement of pharmaceutical mass tort litigation;
• Personal liability concerns for life sciences counsel and other industry professionals;
• Creating exit strategies for mass torts and selecting the most advantageous settlement model;
• Defense tactics for generic and brand pharmaceutical companies after Mensing and Levine (breakout session);
• Combating negative perceptions when selecting and communicating with jurors (breakout session);
• Proactive litigation strategies for responding to government investigations and increased regulatory enforcement (breakout session);
• Navigating unclear disclosure obligations for life sciences companies and counsel (breakout session);
• Diversity: What are corporate counsel looking for and has it fallen by the wayside? (breakout session);
• Post-recall defense strategies for drug and device litigators (breakout session);
• Avoiding new litigation pitfalls arising from emergent social media;
• Implementing strategic tactics for improving mdl logistics and efficiencies;
• View from the Bench: Current judicial views on medical products litigation;
• Avoiding mistakes when using the preemption defense in device cases; and
• Sorting through the science and explaining complex medical data.
In addition, a pre-conference ethics workshop entitled "Practical and Ethical Tools for Successful Mass Tort Litigation" will be offered from 9:30 am to 12:30 pm on December 5, 2011, and a post-conference business development master class entitled "In-House Perspectives on Selection and Evaluation of Outside Counsel" will be offered from 3:15 pm to 5:30 pm on December 7, 2011.
The agenda for the Drug and Medical Device Litigation conference can be found here (Day 1) and here (Day 2). A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.
The registration fee for the conference is $2,595 (conference alone), $3,095 (conference and workshop or master class), or $3,495 (conference, workshop, and master class). Those registering by November 4, 2011 will receive a $200 discount. Those interested in registering for the conference can do so here, by calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.
Patent Docs is a media partner of the Drug and Medical Device Litigation conference.
Comments